ATE500248T1 - Silyl-geschützte hydroxymethyl-carbamoylalkyl- ketone als intermediate in der herstellung von dopamine-beta-hydroxylase inhibitoren - Google Patents

Silyl-geschützte hydroxymethyl-carbamoylalkyl- ketone als intermediate in der herstellung von dopamine-beta-hydroxylase inhibitoren

Info

Publication number
ATE500248T1
ATE500248T1 AT07076122T AT07076122T ATE500248T1 AT E500248 T1 ATE500248 T1 AT E500248T1 AT 07076122 T AT07076122 T AT 07076122T AT 07076122 T AT07076122 T AT 07076122T AT E500248 T1 ATE500248 T1 AT E500248T1
Authority
AT
Austria
Prior art keywords
carbamoylalkyl
silyl
ketones
production
hydroxylase inhibitors
Prior art date
Application number
AT07076122T
Other languages
English (en)
Inventor
David Alexander Learmonth
Da Silva Patricio Manuel Vieira Soares
Alexander Beliaev
Original Assignee
Portela & Ca Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Portela & Ca Sa filed Critical Portela & Ca Sa
Application granted granted Critical
Publication of ATE500248T1 publication Critical patent/ATE500248T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT07076122T 2002-10-11 2003-10-10 Silyl-geschützte hydroxymethyl-carbamoylalkyl- ketone als intermediate in der herstellung von dopamine-beta-hydroxylase inhibitoren ATE500248T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0223719A GB2393958A (en) 2002-10-11 2002-10-11 Peripherally-selective imidazole inhibitors of dopamine-beta-hydroxylase
GB0224306A GB2394223B (en) 2002-10-11 2002-10-18 Peripherally-selective inhibitors of dopamine-beta-hydroxylase and method of their preparation

Publications (1)

Publication Number Publication Date
ATE500248T1 true ATE500248T1 (de) 2011-03-15

Family

ID=9945777

Family Applications (5)

Application Number Title Priority Date Filing Date
AT07076124T ATE500247T1 (de) 2002-10-11 2003-10-10 Verfahren zur herstellung von 3-(1,3- dihydroimidazol-2-thion-1-yl)-chromanen und thiochromanen als dopamin-beta-hydroxylase inhibitor
AT03256420T ATE403652T1 (de) 2002-10-11 2003-10-10 Imidazolderivate und deren verwendung als peripheral-selektive inhibitoren von dopamin-beta-hydroxylasen
AT07076123T ATE550335T1 (de) 2002-10-11 2003-10-10 3,4-dihydro-3-amino-2h-1-benzopyran und - benzothiopyran derivate als dopamine-beta- hydroxylase inhibitoren und verfahren zu ihrer herstellung
AT07076125T ATE505465T1 (de) 2002-10-11 2003-10-10 Chroman- und thiochroman-3-yl-1,3- dihydroimidazole als hemmer der dopamin-beta- hydroxylase und verfahren zu ihrer herstellung
AT07076122T ATE500248T1 (de) 2002-10-11 2003-10-10 Silyl-geschützte hydroxymethyl-carbamoylalkyl- ketone als intermediate in der herstellung von dopamine-beta-hydroxylase inhibitoren

Family Applications Before (4)

Application Number Title Priority Date Filing Date
AT07076124T ATE500247T1 (de) 2002-10-11 2003-10-10 Verfahren zur herstellung von 3-(1,3- dihydroimidazol-2-thion-1-yl)-chromanen und thiochromanen als dopamin-beta-hydroxylase inhibitor
AT03256420T ATE403652T1 (de) 2002-10-11 2003-10-10 Imidazolderivate und deren verwendung als peripheral-selektive inhibitoren von dopamin-beta-hydroxylasen
AT07076123T ATE550335T1 (de) 2002-10-11 2003-10-10 3,4-dihydro-3-amino-2h-1-benzopyran und - benzothiopyran derivate als dopamine-beta- hydroxylase inhibitoren und verfahren zu ihrer herstellung
AT07076125T ATE505465T1 (de) 2002-10-11 2003-10-10 Chroman- und thiochroman-3-yl-1,3- dihydroimidazole als hemmer der dopamin-beta- hydroxylase und verfahren zu ihrer herstellung

Country Status (10)

Country Link
KR (1) KR101350741B1 (de)
CN (1) CN100393715C (de)
AR (2) AR041589A1 (de)
AT (5) ATE500247T1 (de)
CY (2) CY1108452T1 (de)
DE (4) DE60336276D1 (de)
DK (2) DK1908760T3 (de)
ES (5) ES2364919T3 (de)
GB (2) GB2393958A (de)
SI (2) SI1408038T1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0708818D0 (en) * 2007-05-08 2007-06-13 Portela & Ca Sa Compounds
JP6161538B2 (ja) * 2010-12-22 2017-07-12 バイアル−ポルテラ アンド シーエー，エス．エー． 結晶形及びその製造方法
GB201316410D0 (en) * 2013-09-13 2013-10-30 Bial Portela & Ca Sa Processes for preparing peripherally-selective inhibitors of dopamine-?-hydroxylase and intermediates for use therein

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2581556B2 (ja) * 1986-05-06 1997-02-12 メレルダウファーマスーティカルズ インコーポレーテッド 新規なドパミンベ−タヒドロキシラ−ゼ抑制剤
US4868210A (en) 1988-03-30 1989-09-19 Warner-Lambert Company Antihyperlipidemic and antiatherosclerotic compounds and compositions
WO1995029165A2 (en) * 1994-04-26 1995-11-02 Syntex (U.S.A.) Inc. Benzocycloalkylaz0lethione derivatives as dopamin beta-hydroxylase inhibitors

Also Published As

Publication number Publication date
CY1108452T1 (el) 2014-04-09
DE60336772D1 (de) 2011-05-26
GB2393958A (en) 2004-04-14
ATE550335T1 (de) 2012-04-15
DE60336276D1 (de) 2011-04-14
ES2364919T3 (es) 2011-09-16
KR20120038014A (ko) 2012-04-20
CN1726211A (zh) 2006-01-25
ATE500247T1 (de) 2011-03-15
AR095674A2 (es) 2015-11-04
GB2394223B (en) 2007-05-16
ATE505465T1 (de) 2011-04-15
DE60336275D1 (de) 2011-04-14
SI1908760T1 (sl) 2011-05-31
DK1908760T3 (da) 2011-07-25
ES2361938T3 (es) 2011-06-24
SI1408038T1 (sl) 2008-10-31
DE60322642D1 (de) 2008-09-18
ES2309279T3 (es) 2008-12-16
GB2394223A (en) 2004-04-21
DK1408038T3 (da) 2008-11-24
ATE403652T1 (de) 2008-08-15
CY1112457T1 (el) 2015-12-09
ES2361939T3 (es) 2011-06-24
CN100393715C (zh) 2008-06-11
HK1116188A1 (en) 2008-12-19
GB0224306D0 (en) 2002-11-27
AR041589A1 (es) 2005-05-26
ES2384118T3 (es) 2012-06-29
GB0223719D0 (en) 2002-11-20
KR101350741B1 (ko) 2014-01-10

Similar Documents

Publication Publication Date Title
NL1027811A1 (nl) Heterocyclische aminen als remmers 11- -hydroxy-steroïd-dehydrogenase type 1.
CY2015036I1 (el) Νεα παραγωγα οξαζολιδινονης
FR2842417B1 (fr) Composition cosmetique
FR2842416B1 (fr) Composition cosmetique
EP2125870A4 (de) Inhibitoren von hepatitis-c-ns3-protease
DE602004008303D1 (de) Triazolopyrimidinderivate als inhibitoren von glycogensynthasekinase-3
DE602004000740D1 (de) Herstellung von Nuten
DK1811959T4 (da) Oftalmiske sammensætninger
BRPI0716365A2 (pt) "artigo odontolàgico"
DE60304102D1 (de) Hautreinigungszusammensetzung
DE602005018076D1 (de) Enantioselektive herstellung von chinolin-derivaten
FR2888505B1 (fr) Nouvelles compositions cosmetiques amincissantes
BRPI0717671A2 (pt) "irrigador dental"
ATE504556T1 (de) Herstellung von natriumdiformiat
NO20043937L (no) Anvendelse av vitamin D sammensetninger
ITMI20030385A1 (it) Composizione cosmetica comprendente poliisoprene.
EP1650874A4 (de) Viterbi-decoder
ATE394372T1 (de) G-lactamderivate als prostaglandinagonisten
FI20031004A0 (fi) Uusi syötävä koostumus
DE60323456D1 (de) Herstellung von Nanopartikeln
DE602004029836D1 (de) Herstellung von Turbinenelementen
FI20035067L (fi) Parveke tai vastaava
ATE500248T1 (de) Silyl-geschützte hydroxymethyl-carbamoylalkyl- ketone als intermediate in der herstellung von dopamine-beta-hydroxylase inhibitoren
IS8321A (is) Stöðug afbrigði tegaseródvetnismaleats
DE602004013599D1 (de) Herstellung von somatostatinpeptiden

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties